Cargando…
Long non-coding RNA LINC00346 contributes to cisplatin resistance in nasopharyngeal carcinoma by repressing miR-342-5p
Cisplatin has been used as the first-line chemotherapy to treat advanced nasopharyngeal carcinoma (NPC), while acquired cisplatin resistance resulting from epigenetic regulation is not well understood. The relative expression of LINC00346 was detected in healthy persons, cisplatin-sensitive (CS) pat...
Autores principales: | Cui, Zheqing, Pu, Tian, Zhang, Yujie, Wang, Jia, Zhao, Yulin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276527/ https://www.ncbi.nlm.nih.gov/pubmed/32397872 http://dx.doi.org/10.1098/rsob.190286 |
Ejemplares similares
-
Retraction: ‘Long non-coding RNA LINC00346 contributes to cisplatin resistance in nasopharyngeal carcinoma by repressing miR-342-5p’ (2020), by Cui et al.
Publicado: (2023) -
Expression of concern: ‘Long non-coding RNA LINC00346 contributes to cisplatin resistance in nasopharyngeal carcinoma by repressing miR-342-5p’ (2020), by Cui Z et al.
Publicado: (2023) -
microRNA-342-3p targets FOXQ1 to suppress the aggressive phenotype of nasopharyngeal carcinoma cells
por: Cui, Zheqing, et al.
Publicado: (2019) -
New Insights into LINC00346 and its Role in Disease
por: Lu, Juan, et al.
Publicado: (2022) -
Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression
por: Shi, Weidong, et al.
Publicado: (2019)